echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Blood: The cost-effectiveness of using Ilutinib as a first-line therapy in CLL patients

    Blood: The cost-effectiveness of using Ilutinib as a first-line therapy in CLL patients

    • Last Update: 2020-06-16
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit
    The ALLIANCE trial found that the continued use of ilutinib significantly extended the patient's progression-free survival compared to the treatment of elderly patients with chronic lymphocytic leukemia (CLL) in the course of rituximab and phenyartina fixed course of treatmentFor the study, the researchers created a Markov model to assess the cost-benefit of using ilutini on the front line and compare it with the strategy of using Ilutinib as a third-line treatment after the failure of the benzenemm and venetoclax programmeThe transfer probability of randomized experiment is estimated by parameter survival modelLifetime direct health care costs, quality-adjusted life years (QALYs), and incremental cost-effectiveness ratio (ICERs) were calculated from the perspective of U.SpayersThe first-line use of Irutinib improves QALYs compared to third-line therapy, but significantly increases the cost of medical care (cost increases of $612,700), resulting in ICER at $2,350,041/QALYThe monthly cost of Ilutini as a first-line therapy needs to be reduced by 72% to meet the cost-effectiveness of the $150,000/QALY thresholdThe incremental cost of first-line use of Ilutinib was $478,823 compared to second-line therapy, with an incremental effectiveness of 0.05 QALYs and ICER of $9,810,360/QALYThese data suggest that front-line use of Ilutinib is unlikely to be cost-effective for senior CLL patients at current pricesFor most CLL patients, delaying the use of Ilutinib (second- and third-line) until advanced treatment may be a reasonable strategy to limit medical costs without affecting clinical outcomes
    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.